Evidence since 2021 shows that mRNA COVID-19 vaccines were not a one‑off; multiple additional mRNA-based medical products have been developed and brought to market:

• New mRNA COVID‑19 vaccines beyond the original Pfizer/Moderna shots

  • AWcorna (ARCoV), an mRNA COVID‑19 vaccine developed by Walvax/Abogen, received emergency use authorization in Indonesia in September 2022, adding another marketed mRNA COVID product. (en.wikipedia.org)
  • Zapomeran (Kostaive, ARCT‑154), a self‑amplifying mRNA COVID‑19 vaccine, was approved in Japan in November 2023 and later authorized in the EU in February 2025, becoming the first approved self‑amplifying mRNA vaccine. (en.wikipedia.org)
  • Moderna’s next‑generation mRNA‑1283 vaccine (mNEXSPIKE) was approved by the U.S. FDA on May 30, 2025 for adults ≥65 and high‑risk individuals 12–64, as a distinct lower‑dose, refrigerator‑stable mRNA COVID vaccine. (en.wikipedia.org)
  • Regulators have repeatedly approved updated Pfizer–BioNTech and Moderna mRNA formulations (bivalent and variant‑specific boosters, and 2024–25/2025–26 formulas), each marketed as new vaccine products for evolving variants. (en.wikipedia.org)

• Non‑COVID mRNA vaccines (new disease areas)

  • Moderna’s mRESVIA (mRNA‑1345) for respiratory syncytial virus (RSV) was approved by the U.S. FDA in May 2024 for adults ≥60, with its indication expanded in June 2025 to high‑risk adults 18–59. It is widely described as Moderna’s second approved mRNA product and the first mRNA vaccine approved for a disease other than COVID‑19 in the U.S. (investors.modernatx.com)
  • The same RSV mRNA vaccine has also been approved in the EU and Australia, where regulators likewise emphasize it as the first non‑COVID mRNA vaccine in those regions. (news.modernatx.com)

In 2021, only the initial Pfizer–BioNTech and Moderna COVID‑19 vaccines were on the market. By late 2025, there are multiple distinct mRNA COVID vaccines (including self‑amplifying and next‑generation formulations) and at least one major non‑COVID mRNA vaccine (RSV) approved across several jurisdictions. This clearly matches the directional claim that the original COVID vaccines would be just the first breakthrough and that “there’s going to be a lot more” mRNA‑based medical products in the ensuing years.

Given this expansion from essentially two products to a portfolio spanning several companies, formulations, and at least two different diseases, the prediction that many additional mRNA-based medical products would be developed and brought to market after the COVID vaccines has been borne out.